Rx-To-OTC Switches "Not In Financial Interests" Of Manufacturers - Juhl

Three years of market exclusivity following an Rx-to-OTC switch might not be enough of an incentive to encourage manufacturers to apply for switches, former FDA Nonprescription Drugs Advisory Committee chair Randy Juhl, PhD, University of Pittsburgh, suggested at the American Pharmaceutical Association annual meeting March 11.